Synthesis method of reverse deoxyribose phosphoramidite monomer and intermediate compound of reverse deoxyribose phosphoramidite monomer
Through a new synthesis method, the gradual reaction of compound c with ammonium sulfate, palladium carbon, sodium hydroxide and cyano compounds was successfully shortened, and the synthesis route of reverse deoxyribose phosphoramidite monomer was reduced, thus reducing the raw material cost and The product yield is improved and the problems of high cost and low yield in the prior art are solved.
Patent Information
- Application Number
- CN202310592339.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-05-24
AI Technical Summary
The existing reverse deoxyribose residue synthesis methods are expensive, with long synthesis routes and low yields, making it difficult to meet the needs of industrial production.
Using a new synthetic method, by mixing compound c with hexamethyldisilicone, ammonium sulfate was added, followed by palladium carbon in ethyl acetate and ethanol, sodium hydroxide in ethanol and water, and finally in dichloro 2-cyanoethyl N,N-diisopropylchlorophosamine and dicyanoimidazole were added to methane to gradually synthesize the reverse deoxyribose phosphoramidite monomer.
The synthesis route is shortened, the raw material price is reduced, and the product yield is improved, making it suitable for industrial production.
Smart Images

Figure BDA0004245923720000011 
Figure BDA0004245923720000021 
Figure BDA0004245923720000022
Abstract
Description
Technical Field
[0001] The invention relates to the field of organic compound synthesis, and in particular to a method for synthesizing a reverse deoxyribose phosphite monomer and an intermediate compound thereof. Background Art
[0002] Nucleic acid drugs refer to nucleic acids themselves or closely related compounds that can be used to treat diseases, including natural nucleotides and chemically modified nucleotides. They work by specifically recognizing endogenous nucleic acid sequences through a base complementary pairing mechanism. In addition to gene therapy, nucleic acids used for treatment can also inhibit the expression of abnormal proteins associated with the disease by inhibiting the expression of DNA or RNA without affecting the expression of other proteins. Compared with antibody drugs, nucleic acid drugs have shown efficacy and safety that exceed those of antibody drugs, and their relatively small molecular weight facilitates mass production by pharmaceutical companies. These characteristics make nucleic acid drugs promising for use in previously difficult-to-treat cancers and genetic diseases, as well as diseases caused by viral infections such as influenza.
[0003] Reverse abasic residues (invAb) are usually added to the 3' or 5' end of the nucleic acid chain, which is beneficial to enhance the activity of RNAi agents. Reverse deoxyribose residues can be prepared by reacting reverse deoxyribose phosphite monomers with the 3' or 5' end of RNAi. At present, there are few reports on the synthesis methods of reverse deoxyribose residues. The existing synthesis methods have expensive raw materials, long synthesis routes, and low yields (NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, Vol. 22, Nos. 5-8, pp. 1305-1307, 2003). Therefore, it is necessary to develop new synthesis methods for preparing reverse deoxyribose residues.
[0004] In order to overcome the shortcomings of the prior art, the present invention provides a method for synthesizing a reverse deoxyribose phosphite monomer. The present invention has a short synthesis route, cheap raw materials and good product yield. Summary of the invention
[0005] The present invention provides an intermediate compound for synthesizing a reverse deoxyribose phosphoramidite monomer, or a stereoisomer thereof, having a structure shown in Formula I:
[0006]
[0007] in,
[0008] PG 1 is selected from a silyl hydroxy protecting group, an acyl protecting group, an alkoxyalkyl protecting group;
[0009] PG 2 Selected from triphenylmethyl, monomethoxytrityl, dimethoxytrityl or trimethoxytrityl.
[0010] Further, the compound represented by formula I is represented by formula II,
[0011]
[0012] in,
[0013] PG 1 is selected from silyl hydroxy protecting groups; preferably, PG 1 is selected from the group consisting of tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triethylsilyl, triisopropylsilyl, trimethylsilyl, diethylisopropylsilyl, dimethylisopropylsilyl, di-tert-butylmethylsilyl, diphenylmethylsilyl, trimethylsilylethoxymethyl and trimethylsilylethyl; more preferably, PG 1 Selected from tert-butyldimethylsilyl;
[0014] PG 2 is selected from triphenylmethyl, monomethoxytrityl, dimethoxytrityl or trimethoxytrityl; preferably, PG 2 Selected from 4,4'-dimethoxytriphenyl.
[0015] In some embodiments of the present invention, the compound represented by Formula I or Formula II is specifically:
[0016]
[0017] The present invention also provides a method for synthesizing compound d-1, comprising step 1:
[0018]
[0019] Step 1: Compound c is mixed with hexamethyldisilazide, and ammonium sulfate is added to react to obtain compound d-1;
[0020] Among them, R 1 Selected from
[0021] The present invention also provides a method for synthesizing a reverse deoxyribose phosphoramidite monomer using compound d-1, comprising steps 2 to 4:
[0022]
[0023] Step 2: Dissolve compound d-1 in ethyl acetate and ethanol, add palladium carbon, and stir to react at room temperature to obtain compound e-1;
[0024] Step 3: dissolving compound e-1 in ethanol and water, adding sodium hydroxide, and stirring at 60-100° C. for 5-24 hours to obtain compound f-1;
[0025] Step 4: Dissolve compound f-1 in dichloromethane, add 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and dicyanoimidazole, and stir at room temperature for 0.5 to 6 hours to obtain a reverse deoxyribose phosphoramidite monomer.
[0026] The present invention also provides a method for synthesizing a reverse deoxyribose phosphoramidite monomer, comprising step A, step B and steps 2 to 4:
[0027]
[0028] Step A: dissolve a in pyridine, add tert-butyldimethylsilyl chloride, and stir at room temperature for 5 to 24 hours to obtain compound b;
[0029] Step B: dissolve compound b in pyridine, add DMTrCl, and stir the mixture at 30-80°C for 8-24h to obtain compound c;
[0030] Step 1: Compound c is mixed with hexamethyldisilazide, and ammonium sulfate is added to react to obtain compound d-1;
[0031] Step 2: Dissolve compound d-1 in ethyl acetate and ethanol, add palladium carbon, and stir to react at room temperature to obtain compound e-1;
[0032] Step 3: dissolving compound e-1 in ethanol and water, adding sodium hydroxide, and stirring at 60-100° C. for 5-24 hours to obtain compound f-1;
[0033] Step 4: dissolving compound f-1 in dichloromethane, adding 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and dicyanoimidazole, and stirring at room temperature for 0.5 to 6 hours to obtain a reverse deoxyribose phosphoramidite monomer;
[0034] Among them, R 1 Selected from
[0035] Further, the reaction temperature in step 1 is 60-150°C; preferably, the reaction temperature in step 1 is 80-140°C; more preferably, the reaction temperature in step 1 is 80°C, 90°C, 100°C, 110°C, 120°C, 130°C, 140°C.
[0036] Furthermore, the molar equivalent ratio of compound c to ammonium sulfate in step 1 is 1:1-3; preferably, the molar equivalent ratio of compound c to ammonium sulfate in step 1 is 1:1-2; more preferably, the molar equivalent ratio of compound c to ammonium sulfate in step 1 is 1:2.
[0037] Furthermore, the reaction time in step 1 is 1 to 5 hours; preferably, the reaction time in step 1 is 1 hour, 1.5 hours, 2 hours, or 2.5 hours.
[0038] Furthermore, the palladium carbon in step 2 is 10% w / w palladium carbon.
[0039] Furthermore, in step 2, the mass ratio of compound d-1 to palladium carbon is 1:0.1 to 0.2; preferably, in step 2, the mass ratio of compound d-1 to palladium carbon is 1:0.1.
[0040] Further, the reaction time in step 2 is 5 to 24 hours; preferably, the reaction time in step 2 is 8 to 18 hours; more preferably, the reaction time is 10 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours.
[0041] Further, in step 3, the molar equivalent ratio of e-1 to sodium hydroxide is 1:3-8; preferably, in step 3, the molar equivalent ratio of compound e-1 to sodium hydroxide is 1:5-7.
[0042] Furthermore, in step 3, the reaction temperature is 80-100°C; preferably, the reaction temperature is 80°C, 85°C, 90°C, 95°C, or 100°C.
[0043] Furthermore, the reaction time in step 3 is 8 to 18 hours. Preferably, the reaction time is 10 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours.
[0044] Furthermore, in step 4, the molar equivalent ratio of f-1 to 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and dicyanoimidazole is 1:1-1.5:0.5-1.
[0045] Furthermore, the reaction time in step 4 is 0.5 to 3 hours. Preferably, the reaction time is 0.5 hours, 1 hour, 1.5 hours, 2 hours, or 2.5 hours.
[0046] Furthermore, the molar equivalent ratio of compound a to tert-butyldimethylchlorosilane in step A is 1:1-2; preferably, the molar equivalent ratio of compound a to tert-butyldimethylchlorosilane in step A is 1:1-1.5.
[0047] Furthermore, the reaction time in step A is 8 to 18 hours; preferably, the reaction time is 10 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours.
[0048] Further, the molar equivalent ratio of compound b to DMTrCl in step B is 1:1-2; preferably, the molar equivalent ratio of compound b to DMTrCl in step B is 1:1-1.5.
[0049] Furthermore, the reaction time in step B is 10 to 18 hours; preferably, the reaction time is 10 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours.
[0050] Furthermore, in step B, the reaction temperature is 40-60°C; preferably, the reaction temperature is 40°C, 45°C, 50°C, 55°C, or 60°C.
[0051] In the present invention, the term "hydroxyl protecting group" means a group known to those skilled in the art that can prevent a hydroxyl group from undergoing chemical reactions, including a silyl protecting group (such as tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triethylsilyl, triisopropylsilyl, trimethylsilyl, diethylisopropylsilyl, dimethylisopropylsilyl, di-tert-butylmethylsilyl, diphenylmethylsilyl, trimethylsilylethoxymethyl and trimethylsilylethyl), an alkoxyalkyl protecting group (such as methoxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl and tetrahydropyranyl), an acyl protecting group (such as methoxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl and tetrahydropyranyl), protecting groups (e.g., formyl, acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, fluoroacetyl, difluoroacetyl, trifluoroacetyl, bromoacetyl, tribromoacetyl, methoxyacetyl, pivaloyl and benzoyl), alkoxycarbonyl type protecting groups (e.g., methoxycarbonyl, 2,2,2-trichloroethoxycarbonyl and benzyloxycarbonyl), benzyl type protecting groups (e.g., benzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,5-dimethoxybenzyl, 2,3,4-trimethoxybenzyl, 3,4,5-trimethoxybenzyl, 2-nitrobenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 2,6-dichlorobenzyl, 4-cyanobenzyl, diphenylmethyl, triphenylmethyl and 4,4'-dimethoxytrityl).
[0052] In the present invention, DMTr represents 4,4'-dimethoxytriphenyl group.
[0053] The term "inverted abasic residue" is also referred to as an inverted abasic site. The inverted abasic residue may be linked via phosphate, phosphorothioate or other internucleoside linkages.
[0054] The synthetic method of the reverse deoxyribose phosphoramidite monomer of the present invention has a short route, cheap raw materials and good product yield.
[0055] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0056] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 is the H NMR spectrum of compound d-1;
[0058] Figure 2 is the H NMR spectrum of compound e-1;
[0059] Figure 3 is the H NMR spectrum of compound f-1;
[0060] Figure 4 is the hydrogen nuclear magnetic resonance spectrum of compound g-1. Specific implementation plan
[0061] In order to make the purpose, technical solutions and advantages of the present invention more clear, preferred embodiments of the present invention will be described in detail below.
[0062] The abbreviations used are as follows: DMTrCl: 4,4'-bismethoxytrityl chloride; HMDS: hexamethyldisilazane.
[0063] Room temperature refers to 20℃~30℃.
[0064] Example 1
[0065] Synthesis of compound b-1:
[0066]
[0067] 2'-deoxythymidine (a-1, 20 g, 82.6 mmol) was dissolved in pyridine (100 mL) under ice bath, tert-butyldimethylsilyl chloride (13.6 g, 90.9 mmol) was added, and the mixture was stirred at room temperature for 16 hours. Pyridine was evaporated under reduced pressure, and the mixture was cooled to room temperature. The solid was dissolved in ethyl acetate (200 mL), washed three times with water (200 mL), ethyl acetate was evaporated under reduced pressure, and the mixture was cooled to room temperature. Petroleum ether (400 mL) was added to the solid, and the mixture was stirred at room temperature for 4 hours. The mixture was filtered and the solid was dried to obtain compound b-1 (28 g, 78.7 mmol, yield 96%).
[0068] Synthesis of compound c-1:
[0069]
[0070] Compound b-1 (18 g, 50.6 mmol) was dissolved in pyridine (90 mL) at room temperature, DMTrCl (20.5 g, 60.7 mmol) was added, and the mixture was stirred at 50 °C for 16 hours. Pyridine was evaporated under reduced pressure, and the mixture was cooled to room temperature. The solid was dissolved in dichloromethane (200 mL), washed three times with water (200 mL), and dichloromethane was evaporated under reduced pressure. The mixture was purified by column chromatography (PE / EA=5 / 1) to give compound c-1 (26.4 g, 40.1 mmol, yield 79%).
[0071] Synthesis of compound d-1:
[0072]
[0073] Compound c-1 (658 mg, 1 mmol, yield 79%) was mixed with HMDS (4 mL) at room temperature, and ammonium sulfate (264 mg, 2 mmol) was added. The mixture was stirred at 140 °C for 1.5 hours, cooled to room temperature, and the solvent was evaporated under reduced pressure. Compound d-1 (442 mg, 0.83 mmol, yield 83%) was purified by column chromatography.
[0074] Synthesis of compound e-1:
[0075]
[0076] Compound d-1 (13 g, 24.3 mmol) was dissolved in ethyl acetate (100 mL) and ethanol (100 mL) at room temperature, 10% w / w Pd / C (1.3 g) was added, stirred at room temperature for 16 hours, filtered, and the solvent was evaporated under reduced pressure to obtain compound e-1 (12.5 g, 23.4 mmol, yield 96%).
[0077] Synthesis of compound f-1:
[0078]
[0079] Compound e-1 was dissolved in ethanol (80 mL) and water (80 mL) at room temperature, sodium hydroxide (13.6 g, 160 mmol) was added, and the mixture was stirred at 90 ° C for 16 hours. The solvent was evaporated under reduced pressure and cooled to room temperature. The solid was dissolved in dichloromethane (100 mL), washed three times with water (200 mL), and the solvent was evaporated under reduced pressure. Purification by column chromatography (PE / EA=3 / 1) gave compound f-1 (7.3 g, 17.4 mmol, yield 74%).
[0080] Synthesis of compound g-1 (reverse deoxyribose phosphoramidite monomer):
[0081]
[0082] Compound f-1 was dissolved in dichloromethane (50 mL) at room temperature, and 2-cyanoethyl N, N-diisopropylchlorophosphoramidite (6.86 g, 22.8 mmol) and dicyanoimidazole (1.35 g, 11.4 mmol) were added. The mixture was stirred at room temperature for 1 hour, and dichloromethane (50 mL) was added to dilute it. The mixture was washed with water (100 mL) for three times, and the solvent was evaporated under reduced pressure. The mixture was cooled to room temperature to obtain an oily substance which was dissolved in dimethyl sulfoxide (20 mL) and purified by reverse phase column (C18) chromatography (water / acetonitrile = 1 / 4) to obtain compound g-1 (4.6 g, 7.4 mmol, yield 64%).
[0083] The above-mentioned implementation modes are only preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above-mentioned embodiments. Any other changes, modifications, substitutions, combinations and simplifications made without departing from the spirit and principle of the present invention shall be equivalent replacement modes and shall be included in the protection scope of the present invention.
Claims
1. A compound of formula I or a stereoisomer thereof: in, PG 1 is selected from a silyl hydroxy protecting group, an acyl protecting group, an alkoxyalkyl protecting group; PG 2 Selected from triphenylmethyl, monomethoxytrityl, dimethoxytrityl or trimethoxytrityl.
2. The compound according to claim 1, Features: The compound shown in formula I is shown in formula II, in, PG 1 is selected from silyl hydroxy protecting groups; preferably, PG 1 is selected from the group consisting of tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triethylsilyl, triisopropylsilyl, trimethylsilyl, diethylisopropylsilyl, dimethylisopropylsilyl, di-tert-butylmethylsilyl, diphenylmethylsilyl, trimethylsilylethoxymethyl and trimethylsilylethyl; more preferably, PG 1 Selected from tert-butyldimethylsilyl; PG 2 is selected from triphenylmethyl, monomethoxytrityl, dimethoxytrityl or trimethoxytrityl; preferably, PG 2 Selected from 4,4'-dimethoxytriphenyl.
3. The compound according to claim 2, Features: The compound is specifically:
4. A method for synthesizing compound d-1, comprising step 1: Step 1: Compound c is mixed with hexamethyldisilazide, and ammonium sulfate is added to react to obtain compound d-1; in, R 1 Selected from 5. A method for synthesizing a reverse deoxyribose phosphoramidite monomer using compound d-1, comprising steps 2 to 4: Step 2: Dissolve compound d-1 in ethyl acetate and ethanol, add palladium carbon, and stir to react at room temperature to obtain compound e-1; Step 3: dissolving compound e-1 in ethanol and water, adding sodium hydroxide, and stirring at 60-100° C. for 5-24 hours to obtain compound f-1; Step 4: Dissolve compound f-1 in dichloromethane, add 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and dicyanoimidazole, and stir at room temperature for 0.5 to 6 hours to obtain a reverse deoxyribose phosphoramidite monomer.
6. A method for synthesizing a reverse deoxyribose phosphoramidite monomer, comprising step A, step B and steps 2 to 4: Step A: dissolve a in pyridine, add tert-butyldimethylsilyl chloride, and stir at room temperature for 5 to 24 hours to obtain compound b; Step B: dissolve compound b in pyridine, add DMTrCl, and stir the mixture at 30-80°C for 8-24h to obtain compound c; Step 1: Compound c is mixed with hexamethyldisilazide, and ammonium sulfate is added to react to obtain compound d-1; Step 2: Dissolve compound d-1 in ethyl acetate and ethanol, add palladium carbon, and stir to react at room temperature to obtain compound e-1; Step 3: dissolving compound e-1 in ethanol and water, adding sodium hydroxide, and stirring at 60-100° C. for 5-24 hours to obtain compound f-1; Step 4: dissolving compound f-1 in dichloromethane, adding 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and dicyanoimidazole, and stirring at room temperature for 0.5 to 6 hours to obtain a reverse deoxyribose phosphoramidite monomer; in, R 1 Selected from 7. The synthesis method according to claims 4 to 6, Features: The reaction temperature in step 1 is 60 to 150° C.; preferably, the reaction temperature in step 1 is 80 to 140° C.; The molar equivalent ratio of compound c to ammonium sulfate in step 1 is 1:1-3; preferably, the molar equivalent ratio of compound c to ammonium sulfate in step 1 is 1:1-2; The reaction time in step 1 is 1 to 5 hours.
8. The synthesis method according to claims 5 to 6, Features: The mass ratio of compound d-1 to palladium carbon in step 2 is 1:0.1 to 0.2; preferably, the mass ratio of compound d-1 to palladium carbon in step 2 is 1:0.1; The molar equivalent ratio of e-1 to sodium hydroxide in step 3 is 1:3-8; preferably, the molar equivalent ratio of compound e-1 to sodium hydroxide in step 3 is 1:5-7; In step 4, the molar equivalent ratio of f-1 to 2-cyanoethyl N,N-diisopropylchlorophosphoramidite and dicyanoimidazole is 1:1-1.5:0.5-1.
9. The synthesis method according to claims 5 to 6, Features: The palladium carbon in step 2 is 10% w / w palladium carbon; The reaction time in step 2 is 5 to 24 hours; preferably, the reaction time in step 2 is 8 to 18 hours; In step 3, the reaction temperature is 80-100°C; The reaction time in step 4 is 0.5 to 3 hours.
10. The synthesis method according to claim 6, Features: The molar equivalent ratio of compound a to tert-butyldimethylsilyl chloride in step A is 1:1-2; preferably, the molar equivalent ratio of compound a to tert-butyldimethylsilyl chloride in step A is 1:1-1.5; The reaction time in step A is 8 to 18 hours; The molar equivalent ratio of compound b to DMTrCl in step B is 1:1-2; preferably, the molar equivalent ratio of compound b to DMTrCl in step B is 1:1-1.5; The reaction time in step B is 10 to 18 hours; The reaction temperature in step B is 40-60°C.
Citation Information
Patent Citations
Phosphoramidite ester as well as preparation method and application thereof
CN108610360A
C4'-fluorouridine phosphoramidite monomer and preparation method of C4'-fluorouridine modified RNA
CN109134570A
Novel glycoside compound and production method therefor
CN110198948A
2'-C-methyluracil nucleoside phosphoramidite monomer and synthetic method thereof
CN110483604A
Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives
WO2002018405A2
